Citadel Advisors
PMVP icon

Citadel Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Citadel Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.9K Sell
45,048
-73,545
-62% -$93.5K ﹤0.01% 12361
2025
Q4 		$148K Sell
118,593
-74,560
-39% -$99.9K ﹤0.01% 11333
2025
Q3 		$270K Sell
193,153
-63,278
-25% -$87.5K ﹤0.01% 10595
2025
Q2 		$272K Buy
256,431
+242,311
+1,716% +$238K ﹤0.01% 10025
2025
Q1 		$15.4K Sell
14,120
-93,768
-87% -$127K ﹤0.01% 13321
2024
Q4 		$163K Sell
107,888
-947,808
-90% -$1.5M ﹤0.01% 10761
2024
Q3 		$1.57M Sell
1,055,696
-660,778
-38% -$1.02M ﹤0.01% 5964
2024
Q2 		$2.78M Buy
1,716,474
+135,924
+9% +$245K ﹤0.01% 4707
2024
Q1 		$2.69M Buy
1,580,550
+350,200
+28% +$654K ﹤0.01% 4975
2023
Q4 		$3.81M Sell
1,230,350
-692,007
-36% -$1.83M ﹤0.01% 4215
2023
Q3 		$11.8M Sell
1,922,357
-204,464
-10% -$1.41M ﹤0.01% 2471
2023
Q2 		$13.3M Buy
2,126,821
+346,717
+19% +$1.82M ﹤0.01% 2326
2023
Q1 		$8.49M Buy
1,780,104
+404,005
+29% +$2.84M ﹤0.01% 3019
2022
Q4 		$12M Buy
1,376,099
+406,601
+42% +$4.33M ﹤0.01% 2569
2022
Q3 		$11.5M Sell
969,498
-440,580
-31% -$6.37M ﹤0.01% 2566
2022
Q2 		$20.1M Buy
1,410,078
+1,369,096
+3,341% +$19.9M 0.01% 1851
2022
Q1 		$853K Sell
40,982
-119,570
-74% -$2.11M ﹤0.01% 8073
2021
Q4 		$3.71M Buy
160,552
+135,205
+533% +$3.27M ﹤0.01% 4900
2021
Q3 		$755K Sell
25,347
-101,288
-80% -$3.23M ﹤0.01% 8858
2021
Q2 		$4.33M Buy
126,635
+116,602
+1,162% +$3.89M ﹤0.01% 4753
2021
Q1 		$330K Buy
10,033
+3,878
+63% +$153K ﹤0.01% 10617
2020
Q4 		$379K Sell
6,155
-7,220
-54% -$283K ﹤0.01% 8662
2020
Q3 		$475K Buy
+13,375
New +$492K ﹤0.01% 7387

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's PMVP Position: Q1 2026 in Review

Citadel Advisors reduced its PMV Pharmaceuticals (PMVP) stake by 62% in Q1 2026, selling an estimated $93.5K and leaving 45,048 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12361.

Citadel Advisors first reported a position in PMVP in Q3 2020 and has held it in 23 quarters since. The position peaked at $20.1M in Q2 2022. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Citadel Advisors held 45,048 shares of PMV Pharmaceuticals worth $55.9K as of Q1 2026.
  • Citadel Advisors sold 73,545 PMV Pharmaceuticals shares in Q1 2026, an estimated $93.5K.
  • PMV Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12361 holding.
  • Citadel Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's PMV Pharmaceuticals position peaked at $20.1M in Q2 2022.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.